drugset / Trial / NCT06137703

A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers

NCT06137703

Phase 1 Completed 52 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

This trial is designed to compare the rate and extent of absorption of four different formulations of zavegepant. 52 healthy male and female volunteers will receive a single dose of each formulation at least 7 days apart over a period of about 7 weeks and the amount of drug in their blood will be assessed over the 24 hour period after each dose.

Timeline

Start
2022-08-24
Primary completion
2022-12-07
Completion
2022-12-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Zavegepant Small molecule 100 mg
Subject Zavegepant Small molecule 200 mg

Indications

No indication recorded.